Cargando…

Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)

OBJECTIVE: Neurokinin (NK)-3 and NK-1 receptors have been implicated in the etiology of vasomotor symptoms (VMS) and sleep disturbances associated with menopause. This phase 2b, adaptive, dose-range finding study aimed to assess the efficacy and safety of multiple doses of elinzanetant (NT-814), a s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simon, James A., Anderson, Richard A., Ballantyne, Elizabeth, Bolognese, James, Caetano, Cecilia, Joffe, Hadine, Kerr, Mary, Panay, Nick, Seitz, Christian, Seymore, Susan, Trower, Mike, Zuurman, Lineke, Pawsey, Steve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970022/ https://www.ncbi.nlm.nih.gov/pubmed/36720081 http://dx.doi.org/10.1097/GME.0000000000002138

Ejemplares similares

OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1)
por: Simon, James, et al.
Publicado: (2020)

Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women
por: Pawsey, Steve, et al.
Publicado: (2021)

Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial
por: Trower, Mike, et al.
Publicado: (2020)

SUN-LB58 Repeated Once-Daily Administration of the Non-Hormonal Neurokinin 1,3 Receptor Antagonist NT-814 Reduces LH, Estradiol and Progesterone in Healthy Women
por: Dhillo, Waljit Singh, et al.
Publicado: (2020)

Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
por: Gompel, Anne, et al.
Publicado: (2023)

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023)

Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause
por: Conklin, Melissa, et al.
Publicado: (2023)

Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action
por: Prague, Julia K., et al.
Publicado: (2018)

Neurokinin 1 Receptor Antagonists for Pruritus
por: Alam, Majid, et al.
Publicado: (2021)

Neurokinin-1 Receptor Antagonists against Hepatoblastoma
por: Muñoz, Miguel, et al.
Publicado: (2019)

Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN
por: Gold, Ellen B., et al.
Publicado: (2021)

Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause
por: Pinkerton, JoAnn V., et al.
Publicado: (2015)

Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial
por: Vincenzi, Bruno, et al.
Publicado: (2020)

Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN
por: Thurston, Rebecca C., et al.
Publicado: (2021)

Neurokinin-1 Receptor Antagonist Treatment in Polymicrobial Sepsis: Molecular Insights
por: Hegde, Akhil, et al.
Publicado: (2010)

Neurokinin-1 receptor antagonists: A new revolution in antiretroviral treatment?
por: Grewal, Udhayvir Singh
Publicado: (2016)

The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
por: Muñoz, Miguel, et al.
Publicado: (2020)

Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)
por: Santoro, Nanette, et al.
Publicado: (2020)

OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study
por: Fraser, Graeme, et al.
Publicado: (2019)

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
por: Fraser, Graeme L., et al.
Publicado: (2020)

Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK(1)) receptor antagonists
por: Bošnjak, Snežana M., et al.
Publicado: (2017)

The Neurokinin 1 Receptor Antagonist, Ezlopitant, Reduces Appetitive Responding for Sucrose and Ethanol
por: Steensland, Pia, et al.
Publicado: (2010)

The role of neurokinin-1 (substance P) antagonists in the prevention of postoperative nausea and vomiting
por: Okafor, Dionne, et al.
Publicado: (2017)

Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018)

Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists
por: Schöppe, Jendrik, et al.
Publicado: (2019)

Neurokinin-1 Receptor Antagonists as Antitumor Drugs in Gastrointestinal Cancer: A New Approach
por: Muñoz, Miguel, et al.
Publicado: (2016)

Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients
por: Robinson, Prema, et al.
Publicado: (2023)

Treating hot flushes with a neurokinin 3 receptor antagonist
por: Prague, Julia K., et al.
Publicado: (2017)

Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance
por: García-Aranda, Marilina, et al.
Publicado: (2022)

Antagonist of the neurokinin-1 receptor curbs neuroinflammation in ex vivo and in vitro models of Lyme neuroborreliosis
por: Martinez, Alejandra N., et al.
Publicado: (2015)

Role of fosaprepitant, a neurokinin Type 1 receptor antagonist, in morphine-induced antinociception in rats
por: Prasoon, Pranav, et al.
Publicado: (2016)

Evaluation of a Neurokinin-1 Antagonist in Preventing Multiple-day Cisplatin-induced Nausea and Vomiting
por: Li, Quanfu, et al.
Publicado: (2018)

Evaluation of the Antinociceptive Effect of Maropitant, a Neurokinin-1 Receptor Antagonist, in Cats Undergoing Ovariohysterectomy
por: Corrêa, Janaina M. X., et al.
Publicado: (2019)

Neurokinin-1 receptor antagonists for postoperative nausea and vomiting: a systematic review and meta-analysis
por: Murakami, Chiaki, et al.
Publicado: (2020)

The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant
por: Coveñas, Rafael, et al.
Publicado: (2023)

Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
por: Lim, Chae Seong, et al.
Publicado: (2013)

Neurokinin-1 Receptor Antagonists in Preventing Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis
por: Liu, Meng, et al.
Publicado: (2015)

Neurokinin-1 Receptor Inhibition and Cough
por: Turner, Richard D., et al.
Publicado: (2021)

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy
por: Hesketh, Paul J., et al.
Publicado: (2016)

Neurokinin-1 receptor is highly expressed in cervical cancer and its antagonist induces cervical cancer cell apoptosis
por: Guan, Liyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hogqm6scfh25fo0q0hdd71k425